Lipid management in Type 2 diabetes: The case for combination therapy?

Therapy

Volumn 8, Issue 2, 2011, Pages 129-141

  Saely, Christoph H ^a,b,c   Drexel, Veronika ^a   Vonbank, Alexander ^a,b,c   Drexel, Heinz ^a,b,c,d  

^a Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^b Academic Teaching Hospital   (Austria)

^c PRIVATE UNIVERSITY OF THE PRINCIPALITY OF LIECHTENSTEIN   (Liechtenstein)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

anion exchange resins; ezetimibe; fibrates; lipid therapy; niacin; omega 3 fatty acids; pioglitazone; statins; Type 2 diabetes

Indexed keywords

ANACETRAPIB; ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PIOGLITAZONE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LIFESTYLE MODIFICATION; LIPID METABOLISM; MUSCLE DISEASE; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT PLANNING;

EID: 79953250358     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.11.5     Document Type: Review

References (114)

1. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W: Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch. Intern. Med. 167, 1145-1151 (2007).
2. Stancu C, Sima A: Statins: mechanism of action and effects. J. Cell. Mol. Med. 5, 378-387 (2001).
3. Drexel H: Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anionexchange resins, omega-3 fatty acids: which drugs for which patients? Fundam. Clin. Pharmacol. 23, 687-692 (2009). Overview covering the current options of lipid management.
4. Drexel H, Aczel S, Marte T et al.: Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28, 101-107 (2005).
5. Barter P, Gotto AM, LaRosa JC et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301-1310 (2007).
6. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH: Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis 208, 484-489 (2010).
7. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H: The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J. Clin. Endocrinol. Metab. 90, 5698-5703 (2005).
8. Knowler WC, Barrett-Connor E, Fowler SE et al.: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
9. Gardner CD, Kiazand A, Alhassan S et al.: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 297, 969-977 (2007).
10. Johnson JL, Slentz CA, Houmard JA et al.: Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise). Am. J. Cardiol. 100, 1759-1766 (2007).
11. Deeg MA, Buse JB, Goldberg RB et al.: Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 30, 2458-2464 (2007).
12. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005). This meta-analysis firmly establishes the efficacy and safety of statin therapy.
13. Colhoun HM, Betteridge DJ, Durrington PN et al.: Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
14. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425-1435 (2005). Proves the efficacy of high-dose atorvastatin to reduce cardiovascular events in patients with stable coronary artery disease over and above standard statin therapy.
15. Shepherd J, Barter P, Carmena R et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29, 1220-1226 (2006).
16. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STALLAR trial). Am. J. Cardiol. 92, 152-160 (2003).
17. Auwerx J, Schoonjans K, Fruchart JC, Staels B: Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124(Suppl.), S29-S37 (1996).
18. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR: The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am. Heart J. 154, 943-953 (2007).
19. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ: Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab. Res. Rev. 15, 395-399 (1999).
20. Vakkilainen J, Steiner G, Ansquer JC et al.: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107, 1733-1737 (2003).
21. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am. J. Cardiol. 95, 462-468 (2005).
22. Franssen R, Vergeer M, Stroes ES, Kastelein JJ: Combination statin-fibrate therapy: safety aspects. Diabetes Obes. Metab. 11, 89-94 (2009).
23. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95, 120-122 (2005).
24. Frick MH, Elo O, Haapa K et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987).
25. Rubins HB, Robins SJ, Collins D et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med. 162, 2597-2604 (2002).
26. Rubins HB, Robins SJ, Collins D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410-418 (1999).
27. Harper CR, Jacobson TA: The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 18, 401-408 (2007).
28. McClure DL, Valuck RJ, Glanz M, Murphy JR, Hokanson JE: Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J. Clin. Epidemiol. 60, 812-818 (2007).
29. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch. Intern. Med. 165, 1154-1160 (2005).
30. Peters JM, Aoyama T, Burns AM, Gonzalez FJ: Bezafibrate is a dual ligand for PPARa and PPARb: studies using null mice. Biochim. Biophys. Acta 1632, 80-89 (2003).
31. Hiuge A, Tenenbaum A, Maeda N et al.: Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler. Thromb. Vasc. Biol. 27, 635-641 (2007).
32. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
33. Ginsberg HN, Elam MB, Lovato LC et al.: Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010). Addresses the efficacy of fenofibrate to reduce cardiovascular events over and above simvastatin monotherapy.
34. Tenenbaum A, Fisman EZ: "If it ain't broke, don't fix it": a commentary on the positivenegative results of the ACCORD Lipid study. Cardiovasc. Diabetol. 9, 24 (2010).
35. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357, 905-910 (2001).
36. Jun M, Foote C, Lv J et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 375, 1875-1884 (2010).
37. Perkins WJ Jr: Combination lipid therapy in Type 2 diabetes. N. Engl. J. Med. 363, 694-695 (2010).
38. Rubenfire M, Brook RD, Rosenson RS: Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am. J. Med. 123, 892-898 (2010).
39. Durrington PN, Bhatnagar D, Mackness MI et al.: An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85, 544-548 (2001).
40. Harris WS: Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. Pharmacol. Res. 55, 217-223 (2007).
41. Balk E, Chung M, Lichtenstein A et al.: Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid. Rep. Technol. Assess 93, 1-6 (2004).
42. Davidson MH: Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am. J. Cardiol. 98, 27I-33I (2006).
43. Donnelly SM, Ali MA, Churchill DN: Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J. Am. Soc. Nephrol. 2, 1634-1639 (1992).
44. Bays HE, Maki KC, McKenney J et al.: Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr. Med. Res. Opin. 26, 907-915 (2010).
45. Burr ML, Fehily AM, Gilbert JF et al.: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet And Reinfarction Trial (DART). Lancet 2, 757-761 (1989).
46. Yokoyama M, Origasa H, Matsuzaki M et al.: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090-1098 (2007).
47. Tavazzi L, Maggioni AP, Marchioli R et al.: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223-1230 (2008).
48. Hooper L, Thompson RL, Harrison RA et al.: Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 332, 752-760 (2006).
49. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J: Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine InterventioN). Am. Heart J. 155, 26-32 (2008).
50. Nicholls SJ, Lundman P, Tardif JC: Diabetic dyslipidemia: extending the target beyond LDL cholesterol. Eur. J. Cardiovasc. Prev. Rehabil. 17 (Suppl. 1), S20-S24 (2010).
51. Mazzone T, Meyer PM, Feinstein SB et al.: Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 296, 2572-2581 (2006).
52. Nissen SE, Nicholls SJ, Wolski K et al.: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299, 1561-1573 (2008).
53. Davidson M, Meyer PM, Haffner S et al.: Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with Type 2 diabetes mellitus. Circulation 117, 2123-2130 (2008).
54. Dormandy JA, Charbonnel B, Eckland DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
55. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298, 1180-1188 (2007).
56. Nissen SE, Wolski K: Rosiglitazone Revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
57. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al.: Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304, 411-418 (2010).
58. Shah P, Mudaliar S: Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf. 9, 347-354 (2010).
59. Kamanna VS, Kashyap ML: Mechanism of action of niacin. Am. J. Cardiol. 101, 20B-26B (2008).
60. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH: Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am. J. Cardiol. 101, 1428-1436 (2008).
61. Guyton JR, Bays HE: Safety considerations with niacin therapy. Am. J. Cardiol. 99, 22C-31C (2007).
62. Brown BG, Stukovsky KH, Zhao XQ: Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr. Opin. Lipidol. 17, 631-636 (2006).
63. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231, 360-381 (1975).
64. Canner PL, Berge KG, Wenger NK et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245-1255 (1986).
65. Canner PL, Furberg CD, McGovern ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol. 97, 477-479 (2006).
66. Brown BG, Zhao XQ, Chait A et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
67. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA: Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2, a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
68. Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intimamedia thickness: ARBITER 3. Curr. Med. Res. Opin. 22, 2243-2250 (2006).
69. Brown G, Albers JJ, Fisher LD et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323, 1289-1298 (1990).
70. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264, 3013-3017 (1990).
71. Zhao XQ, Krasuski RA, Baer J et al.: Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces REGression Study (AFREGS). Am. J. Cardiol. 104, 1457-1464 (2009).
72. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF: Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357, 577-581 (2001).
73. Crouse JR III, Raichlen JS, Riley WA et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297, 1344-1353 (2007).
74. Taylor AJ, Villines TC, Stanek EJ et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113-2122 (2009). Compares the impact of niacin versus ezetimibe on the change in carotid intima-media thickness in patients receiving statin treatment.
75. Bitzur R, Cohen H, Kamari Y, Shaish A, Harats D: Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 32(Suppl. 2), S373-S377 (2009).
76. Paolini JF, Mitchel YB, Reyes R et al.: Effects of laropiprant on nicotinic acidinduced flushing in patients with dyslipidemia. Am. J. Cardiol. 101, 625-630 (2008).
77. Barter PJ, Caulfield M, Eriksson M et al.: Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
78. Miyares MA: Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors. Ann. Pharmacother. 45(1), 84-94 (2011).
79. Cannon CP, Shah S, Dansky HM et al.: Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363, 2406-2415 (2010).
80. King A: Coronary heart disease: new hope for CETP inhibitors. Nat. Rev. Cardiol. 8, 5 (2011).
81. Bays HE, Neff D, Tomassini JE, Tershakovec AM: Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc. Ther. 6, 447-470 (2008).
82. Rossebo AB, Pedersen TR, Allen C et al.: Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am. J. Cardiol. 99, 970-973 (2007).
83. Peto R, Emberson J, Landray M et al.: Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359, 1357-1366 (2008).
84. Kastelein JJ, Akdim F, Stroes ES et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
85. Howard BV, Roman MJ, Devereux RB et al.: Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 299, 1678-1689 (2008).
86. Fleg JL, Mete M, Howard BV et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52, 2198-2205 (2008).
87. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J. Am. Coll. Cardiol. 46, 1855-1862 (2005).
88. Rossebo AB, Pedersen TR, Boman K et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359, 1343-1356 (2008).
89. Holme I, Boman K, Brudi P et al.: Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am. J. Cardiol. 105, 1802-1808 (2010).
90. Baigent C, Landry M: Study of Heart And Renal Protection (SHARP). Kidney Int. 84(Suppl.), S207-S210 (2003).
91. Black DM: Gut-acting drugs for lowering cholesterol. Curr. Atheroscler. Rep. 4, 71-75 (2002).
92. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in incidence of coronary heart disease. JAMA 251, 351-364 (1984).
93. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR: Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled Type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31, 1479-1484 (2008).
94. Braunlin W, Zhorov E, Guo A et al.: Bile acid binding to sevelamer HCl. Kidney Int. 62, 611-619 (2002).
95. Insull W Jr, Toth P, Mullican W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. 76, 971-982 (2001).
96. Davidson MH, Dillon MA, Gordon B et al.: Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. 159, 1893-1900 (1999).
97. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158, 407-416 (2001).
98. Knapp HH, Schrott H, Ma P et al.: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. 110, 352-360 (2001).
99. Garg A, Grundy SM: Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann. Intern. Med. 121, 416-422 (1994).
100. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL: Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with Type 2 diabetes. Clin. Ther. 29, 74-83 (2007).
101. Bays HE, Goldberg RB, Truitt KE, Jones MR: Colesevelam hydrochloride therapy in patients with Type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch. Intern. Med. 168, 1975-1983 (2008).
102. American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care 34(Suppl. 1), S11-S61 (2011). Summarizes the American Diabetes Association's current recommendations on the clinical management of patients with diabetes.
103. Toth PP, Zarotsky V, Sullivan JM, Laitinen D: Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis. Cardiovasc. Diabetol. 8, 26 (2009).
104. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 23-33 (2002).
105. Knopp RH, Gitter H, Truitt T et al.: Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J. 24, 729-741 (2003).
106. Clark RW, Sutfin TA, Ruggeri RB et al.: Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24, 490-497 (2004).
107. Robinson JG, Wang S, Smith BJ, Jacobson TA: Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol. 53, 316-322 (2009).
108. Derosa G, Salvadeo SA: Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr. Clin. Pharmacol. 3, 77-84 (2008).
109. Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 65, 1645S-1654S (1997).
110. NHMRC Clinical Trials Centre. Fenofibrate reduces the risk of amputations in patients with Type 2 diabetes www.fieldstudy.info/investigators/CTC-PR-2008. asp (Accessed 19 January 2011)
111. AIM - HIGH trial Niacin Plus Statin to Prevent Vascular Events http://clinicaltrials.gov/ct2/show/NCT00120289 (Accessed 19 January 2011)
112. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE http://clinicaltrials.gov/ct2/show/NCT00461630?term=HPS-2-THRIVE&rank=1 (Accessed 19 January 2011)
113. SHARP: Study of Heart and Renal Protection www.ctsu.ox.ac.uk/~sharp/ (Accessed 19 January 2011)
114. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (Study P04103AM3) http://clinicaltrials.gov/ct2/show/NCT00202878?term=improve+it&rank=1 (Accessed 19 January 2011)